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Peptidoglycan recognition proteins (PGRPs) are
structurally conserved from insects to mammals.
Insect PGRPs have diverse host-defense func-
tions. Mammalian PGRPs PGLYRP-1, PGLYRP-3,
and PGLYRP-4 have bactericidal activity, while
PGLYRP-2 has amidase activity. To extend the
known functions of mammalian PGRPs, we exam-
ined whether they have immunomodulating activities
in peptidoglycan-induced arthritis in mice. We
demonstrate that PGLYRP-2 and Nod2 are both
required for arthritis in this model. The sequence
of events in peptidoglycan-induced arthritis is
activation of Nod2, local expression of PGLYRP-2,
chemokine production, and recruitment of neutro-
phils into the limbs, which induces acute arthritis.
Only PGLYRP-2 among the four mammalian
PGRPs displays this proinflammatory function, and
PGLYRP-1 is anti-inflammatory. Toll-like receptor 4
(TLR4) and MyD88 are required for maturation of
neutrophils before peptidoglycan challenge. Our
results demonstrate that PGRPs, Nod2, and TLR4,
representing three different types of pattern-recogni-
tion molecules, play interdependent in vivo roles in
local inflammation.
INTRODUCTION
Innate immunity is crucial for defense against infections, for trig-
gering acquired immune responses, and for maintaining
a balance between efficient and prompt protective responses
to microbial infections and tolerance to constant exposure to
normal flora and environmental microorganisms. Inappropriate
deployment of immune effectors may result in pathology, such
as septic shock or inflammatory or autoimmune diseases.
Peptidoglycan is an essential and unique component of the
cell walls of virtually all bacteria. Because peptidoglycan is not
found in eukaryotic cells, it is an excellent target for recognition
by the innate immune system. Peptidoglycan is recognized
by several mammalian innate immunity proteins, includingCell Homembers of the Nod-like receptors (NLRs), peptidoglycan
recognition proteins (PGRPs or PGLYRPs), CD14, Toll-like
receptor 2 (TLR2), mannose-binding lectin, RegIIIg C-type lectin,
and lysozyme (Royet and Dziarski, 2007).
NLRs are intracellular pattern recognition receptors that
recognize peptidoglycan fragments, either mesodiaminopimelic
acid-containing peptides found in Gram-negative bacteria and
Gram-positive bacilli (Nod1) (Chamaillard et al., 2003; Girardin
et al., 2003a), or muramyl dipeptide (MDP) found in virtually all
bacteria (Nod2, NALP1, and NALP3) (Inohara et al., 2003; Girar-
din et al., 2003b; Faustin et al., 2007; Martinon et al., 2004).
Mutations in Nod2 are associatedwith Crohn’s disease, an intes-
tinal inflammatory disease likely triggered by bacteria that can be
accompanied by arthritis (Hugot et al., 2001; Ogura et al., 2001),
and Blau syndrome, a disorder characterized by granulomatous
arthritis (Miceli-Richard et al., 2001). However, the role of Nod2 in
the development of arthritis is unclear.
PGRPs are innate immunity proteins that are conserved from
insects to mammals, recognize bacterial peptidoglycan, and
function in antibacterial immunity. Insects have many PGRPs
with diverse functions, such as activation of Toll or IMD signal-
transduction pathways (which result in induction of antimicrobial
peptides), activation of the prophenoloxidase cascade (which
also generates antimicrobial products), induction of phagocy-
tosis, hydrolysis of peptidoglycan, and downregulation of
immune responses (Royet and Dziarski, 2007).
Mammals have four PGRPs, PGLYRP-1, -2, -3, and -4 (initially
named PGRP-S, -L, -Ia, and -Ib, respectively) (Kang et al., 1998;
Liuetal., 2001). Incontrast to insects, thereareonly twoknownfunc-
tions of mammalian PGRPs: PGLYRP-1 (found in PMN’s granules)
and PGLYRP-3 and -4 (found in the skin, eyes, salivary glands,
throat, tongue, esophagus, stomach, and intestine) are directly
bactericidal (Lu et al., 2006;Wang et al., 2007), whereas PGLYRP-2
(which is constitutively expressed in the liver and secreted into
blood) is an N-acetylmuramoyl-L-alanine amidase that hydrolyzes
peptidoglycan (Gelius et al., 2003; Wang et al., 2003).
Because insect PGRPs with peptidoglycan-hydrolytic activity
have anti-inflammatory properties and protect insects from
excessive inflammation induced by proinflammatory peptido-
glycan (Mellroth et al., 2003; Zaidman-Remy et al., 2006;
Bischoff et al., 2006), we set out to test whether amidase-active
mammalian PGLYRP-2 plays a similar anti-inflammatory role
in vivo. To test this hypothesis, we selected peptidoglycan-
induced arthritis model.st & Microbe 5, 137–150, February 19, 2009 ª2009 Elsevier Inc. 137
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PGLYRP-2, Nod2, and TLR4 in ArthritisArthritis is a frequent sequela of bacterial infections, associ-
ated with streptococcal rheumatic fever, gastrointestinal infec-
tions, urinary tract infections, gonorrhea, bacterial overgrowth
in intestinal bypass surgery, inflammatory bowel disease, and
Lyme disease. The pathogenesis of these arthritic diseases is
still poorly understood, but their unifying feature is the absence
of local infection of the joints with bacteria. Thus, this arthritis
is likely caused by proinflammatory bacterial components
deposited in the joints and can be reproduced in a rat model of
chronic relapsing arthritis, in which rats are given one systemic
injection of bacterial peptidoglycan-polysaccharide complex,
which results in initial acute inflammation of the joints, followed
by several bouts of chronic, erosive polyarthritis (Cromartie
et al., 1977; Lehman et al., 1983). The active component of
bacterial cell wall that induces this arthritis is peptidoglycan
(Fox et al., 1982; Stimpson et al., 1987), and the severity of
arthritis correlates with the persistence of peptidoglycan in the
joints (Dalldorf et al., 1980; Eisenberg et al., 1982). Peptidoglycan
is also arthritogenic in other animal models of arthritis, such as
adjuvant arthritis in rats (Kohashi et al., 1976; Chang et al.,
1981), intraperitoneal or intradermal injection model in rats
(Speer et al., 1987; Simelyte et al., 2003), intra-articular injection
model in mice (Joosten et al., 2003), and intravenous injection
model in mice (Koga et al., 1985; Onta et al., 1993). We selected
the latter model because its acute phase is likely based on pepti-
doglycan-induced innate immune response, andwe could there-
fore examine the role of PGRPs and NLRs in its pathogenesis.
If the in vivo function of mammalian PGLYRP-2 were similar to
the anti-inflammatory properties of amidase-active insect
PGRPs, one would expect enhancement of peptidoglycan-
induced arthritis in PGLYRP-2/ mice. Surprisingly, we
discovered the opposite effect; i.e., PGLYRP-2 was required
for the induction of peptidoglycan-induced arthritis, because
PGLYRP-2/ mice were resistant to peptidoglycan-induced
arthritis. Because there are multiple peptidoglycan-recognition
mechanisms and because proteins function in vivo in highly
interactive modules, we also asked whether PGRPs interact
with other innate immunity receptors, such as NLRs and TLRs.
We demonstrate that peptidoglycan activates Nod2, which
induces local PGLYRP-2 expression. PGLYRP-2 then enhances
local production of chemokines, which induce local inflamma-
tion. This function is unique for PGLYRP-2 and is not exhibited
by other PGLYRPs. TLR4 works independently of peptidoglycan
and is required for maturation of neutrophils, which are the main
effectors of arthritis and local inflammation. These results reveal
in vivo functions of PGLYRP-2, Nod2, and TLR4 that define
several steps in the pathogenesis of peptidoglycan-induced
arthritis.
RESULTS
PGLYRP-2 Is Required for the Development
of Peptidoglycan- or MDP-Induced Arthritis
Following intravenous injection of Staphylococcus aureus
peptidoglycan, wild-type (WT) BALB/c mice developed acute
transient arthritis that was most evident in the hind legs and
had a gross appearance of swelling and redness of primarily
the ankle joint, and in more severe cases, of the digits and the
entire foot (Figure 1A). The inflammation peaked on day 3 and138 Cell Host & Microbe 5, 137–150, February 19, 2009 ª2009 Elsegradually subsided by day 8–12 postinjection (Figure 1B). The
incidence of arthritis in WT mice was 60% (Figure 1B).
Transient acute arthritis also developed in WT mice following
intravenous injection of MDP, a synthetic peptidoglycan frag-
ment (Figures 1A and 1B). The MDP-induced arthritis also
primarily involved the ankle joint (Figure 1A), and its incidence
was 80%–90%, but it was short-lived—the inflammation
peaked on day 1 and quickly subsided (Figure 1B).
By contrast, PGLYRP-2/ mice were completely resistant to
the development of arthritis following injection of peptidoglycan
or MDP or coadministration of peptidoglycan and MDP
(Figures 1A and 1B). Unlike PGLYRP-2/ mice, PGLYRP-1/,
PGLYRP-3/, and PGLYRP-4/ mice all developed peptido-
glycan- and MDP-induced arthritis of similar severity and inci-
dence as WT mice (Figure 1C). However, MDP-induced arthritis
in PGLYRP-1/ mice lasted significantly longer than in WT
mice. These results demonstrate that the requirement for
PGLYRP-2 for the development of peptidoglycan- and MDP-
induced acute arthritis is unique among the four mammalian
PGLYRPs.
Histologically, peptidoglycan-induced inflammation in WT
mice was characterized by prominent edema and cellular infiltra-
tions of tendons, tendon sheaths, synovial membrane, subsyno-
vial tissue, synovial space, and connective and subcutaneous
tissues (Figure 2A). Polymorphonuclear leukocytes (PMNs)
were the predominant cells, but mononuclear cells and prolifer-
ating tissue fibroblasts were also present. These changes are
characteristic of acute tendonitis and arthritis, and they were
also observed in WT mice coinjected with peptidoglycan and
MDP (Figure 2B). By contrast, these changes were not observed
in the limbs in peptidoglycan- or peptidoglycan+MPD-injected
PGLYRP-2/ mice, whose feet appeared normal (Figure 2).
MDP-injected WT mice had less severe cellular infiltrates, but
numerous inflammatory cells (primarily PMNs) were still seen in
synovial and subsynovial tissues, tendon sheaths, and other
surrounding tissues. Such infiltrates were not observed in
MPD-injected PGLYRP-2/mice, whose feet appeared normal
(Figure S1A). These results demonstrate that PGLYRP-2 is
required for the development of pathologic changes in peptido-
glycan- and MDP-induced acute tendonitis and arthritis.
Nod2 Is Required for the Development
of Peptidoglycan- or MDP-Induced Arthritis
We next tested whether Nod2 was required for the development
of peptidoglycan- and MDP-induced arthritis, because this
arthritis was induced by both peptidoglycan and MDP, and
Nod2 is a well-characterized receptor for MDP, which is the
minimum active component of all peptidoglycans (Inohara
et al., 2003; Girardin et al., 2003b). In contrast to WT mice,
Nod2/ mice were completely resistant to the development of
arthritis following injection of not only MDP, but also peptido-
glycan or a mixture of peptidoglycan and MDP (Figure 1B).
Because Nod2 is specific for MDP containing L-Ala-D-isoGlu
and does not respond to MurNAc-L-Ala-L-isoGlu (MDP-LL), we
further confirmed the requirement for Nod2 by demonstrating
that MDP-LL was completely inactive and did not induce arthritis
in WT mice (Figure 1B). These results demonstrate that Nod2 is
required for the development of both peptidoglycan- and MDP-
induced arthritis.vier Inc.
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PGLYRP-2, Nod2, and TLR4 in ArthritisFigure 1. PGLYRP-2 and Nod2 Are Required for the Development of Peptidoglycan- or MDP-Induced Acute Arthritis
(A) Swelling and erythema of ankles and feet in WT but not in PGLYRP-2/ mice after intravenous injection of 200 mg peptidoglycan (PGN) or 100 mg MDP.
(B and C) Arthritis scores and incidence in WT or knockout mice after intravenous injection of 200 mg PGN, 100 mg MDP, or both PGN and MDP; means ± SEM of
19–76 mice/group. Arthritis scores and incidence were significantly higher in PGN-injected, MDP-injected, and PGN+MDP-injected WT than in PGLYRP-2/
and Nod2/ mice; in PGN-injected and MDP-injected WT than in PGLYRP-1/PGLYRP-2/ mice; and also in PGN-injected and MDP-injected PGLYRP-
1/PGLYRP-2/ than in PGLYRP-2/ mice (B). Arthritis scores and incidence were not significantly different in PGN-injected or MDP-injected WT than in
PGLYRP-1/, PGLYRP-3/, and PGLYRP-4/ mice, except for PGLYRP-1/ mice, which after MDP injection had significantly higher scores than
WT mice (C). The P values for the significance of all the above differences are listed in Supplemental Data.PGLYRP-1 Opposes the Effect of PGLYRP-2 on the
DevelopmentofPeptidoglycan-orMDP-InducedArthritis
Because MDP-induced arthritis in PGLYRP-1/ mice lasted
significantly longer than in WT mice (Figure 1C), we then testedCell Hosthe possibility that PGLYRP-1 may have an effect opposite to
PGLYRP-2 on the development of arthritis using double
knockout PGLYRP-1/PGLYRP-2/ mice. These mice,
following injection of peptidoglycan or MDP, developed arthritist & Microbe 5, 137–150, February 19, 2009 ª2009 Elsevier Inc. 139
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PGLYRP-2, Nod2, and TLR4 in Arthritisof significantly higher severity and incidence than PGLYRP-2/
mice, although of significantly lower severity and incidence than
peptidoglycan- or MDP-induced arthritis in WT mice (Figure 1B).
These results suggest that PGLYRP-1 and PGLYRP-2 may have
opposing anti-inflammatory and proinflammatory effects,
respectively.
MDP Strongly Induces Chemokine and Cytokine mRNA
in the Feet in WT, PGLYRP-1/, PGLYRP-3/,
and PGLYRP-4/ Mice, but Not in PGLYRP-2/
and Nod2/ Mice
To further define the mechanism of peptidoglycan-induced
arthritis, we focused on MDP, because MDP is the smallest
synthetic peptidoglycan fragment that induces arthritis and
because there is only one class of receptors for MDP (NLRs).
Because the arthritic lesions were characterized by acute inflam-
mation and infiltration with PMNs, we next determined whether
intravenous injection of MDP induced local production of
chemokines and other proinflammatory mediators in the foot.
In WT mice, intravenous injection of MDP significantly
increased expression of 43 proinflammatory genes in the foot
out of a total of 84 genes studied, as determined by quantitative
real-time PCR (qPCR) of mRNA; 29 of these genes were induced
2- to 20-fold (Figure 3 and Table S1). By contrast, intravenous
injection of MDP into PGLYRP-2/mice significantly increased
expression of only 19 out of 84 genes in the foot, 11 of which
were induced 2- to 6-fold (Figure 3 and Table S1). Overall, 34
out of 84 genes were induced significantly higher in WT than in
PGLYRP-2/ mice; 17 of these genes were induced 2- to
9-fold higher in WT than in PGLYRP-2/ mice. These genes
were primarily chemokines (fold induction in WT/fold induction
in PGLYRP-2/ mice): Ccl7 (MCP-3, 8.9), Ccl2 (MCP-1, 7.3),
CCL12 (MCP-5, 6.1), Cxcl1 (KC, 2.9), Cxcl5 (ENA-78, 2.8), Ccl5
(RANTES, 2.7), Cxcl9 (Mig, 2.7), Ccl17 (2.6), Ccl4 (MIP-1b, 2.4),
Ccl19 (MIP-3b, 2.4), and Ccl20 (MIP-3a, 2.3); chemokine
receptors: Ccr5 (2.5) and Ccr4 (2.3); and cytokines and other
proinflammatory molecules: IL-20 (3.6), IL-1b (3.2), C-reactive
protein (2.5), TNF-a (2.1), and IL-6 (5.8, not included in the array).
These differences in induction of genes inWT and PGLYRP-2/
micewere not due to the differences in the basal expression of all
tested genes between WT and PGLYRP-2/ mice, which in
general were similar (differed less than 2-fold, Figure S2 and
Table S4).
These results demonstrate that PGLYRP-2 is required for the
full stimulation of expression of chemokines and other proinflam-
matorymediators genes byMDP in the foot. This low induction of
proinflammatory genes in the foot correlates with the inability of
MDP to induce arthritis in PGLYRP-2/ mice.
By contrast, gene activation in the feet of PGLYRP-1/,
PGLYRP-3/, and PGLYRP-4/ mice after systemic injection
of MDP was generally higher than in WT mice (Figure 3 and
Table S2). Baseline levels of gene expression in untreatedCell HosPGLYRP-1/, PGLYRP-3/, and PGLYRP-4/ mice were
also usually somewhat higher than in WT mice (Figure S2 and
Table S4). These data suggest that in contrast to PGLYRP-2,
which has a proinflammatory effect, other PGLYRPs may have
opposing anti-inflammatory effects.
We next tested whether Nod2 was the MDP receptor required
for the induction of proinflammatory genes in the feet of MDP-
injected mice. Intravenous injection of MDP into Nod2/ mice
did not significantly increase the expression of proinflammatory
genes in their feet (except for 1 out of 84 genes). Thus, 32 out
of 84 genes were induced significantly higher in WT than in
Nod2/ mice, 22 of which were induced 2- to 23-fold higher
inWT than in Nod2/mice (Figure 3 and Table S1). These differ-
ences in induction of genes in WT and Nod2/ mice were not
due to the differences in the basal expression of all tested genes
between WT and Nod2/ mice, which in general were similar
(Figure S2 and Table S4). These data demonstrate that Nod2 is
required for MDP-induced stimulation of expression of chemo-
kines and other proinflammatory genes in the foot and confirm
that Nod2 is the main MDP receptor in the foot. This lack of
induction of proinflammatory genes in the foot of Nod2/ mice
is likely responsible for the inability of MDP and peptidoglycan to
induce arthritis in Nod2/ mice.
PGLYRP-1 Opposes the Effect of PGLYRP-2
in MDP-Induced Activation of ProInflammatory Genes
Because PGLYRP-1 opposed the effect of PGLYRP-2 on the
development of arthritis (Figures 1B and 1C), we next tested
whether PGLYRP-1 also opposes the effect of PGLYRP-2 on
induction of chemokines and other proinflammatory genes in
the foot. Double-knockout PGLYRP-1/PGLYRP-2/ mice
had significantly higher induction of proinflammatory genes
than PGLYRP-2/ mice (Figure 3 and Table S3), which is
consistent with the hypothesis that PGLYRP-2 has proinflamma-
tory and PGLYRP-1 has anti-inflammatory effects.
MDP Induces Similar Chemokine and Cytokine mRNA
Levels in the Liver in WT and PGLYRP-2/ Mice
To determinewhether this defect in proinflammatory gene induc-
tion in response to systemic injection of MDP in PGLYRP-2/
mice was local (in the foot) or general (in all tissues), we also
measured changes in the expression of the same genes in the
same mice in the liver. Intravenous injection of MDP induced
responses in the livers of PGLYRP-2/mice similar to or higher
than in WT mice, and several genes were induced significantly
higher in PGLYRP-2/ than in WT mice (Figure 3 and Table
S3). The basal expression of all 84 genes was similar in the liver
in WT and PGLYRP-2 knockout mice (Figure S2 and Table S4).
These results demonstrate that, in contrast to the foot, in the liver
PGLYRP-2 is not required for full MDP-induced stimulation of
expression of chemokines and other proinflammatory mediators
genes.Figure 2. PGLYRP-2 Is Required for the Development of Peptidoglycan- or Peptidoglycan+MDP-Induced Pathologic Changes Characteristic
of Acute Arthritis
(A and B) Edema and cellular infiltrations of tendons (T), tendon sheaths (TS), synovial membrane (SM), subsynovial tissue (ST), synovial space (SS), and connec-
tive and subcutaneous tissues (SC) in ankles and feet in WT but not in PGLYRP-2/mice 3 days after intravenous injection of 200 mg PGN (A) or 200 mg PGN plus
100 mg MDP (B). PMNs were the predominant infiltrating cells in WT mice (bottom left panels in [A] and [B]). Ankles and feet in injected PGLYRP-2/ mice
appeared normal. Bar = 100 mm in four top panels and 10 mm in four bottom panels.t & Microbe 5, 137–150, February 19, 2009 ª2009 Elsevier Inc. 141
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PGLYRP-2, Nod2, and TLR4 in ArthritisFigure 3. MDP Strongly Induces Chemokine and Cytokine mRNA in the Feet in WT, PGLYRP-1/, PGLYRP-3/, and PGLYRP-4/, but Not
in PGLYRP-2/ and Nod2/ Mice
WT or knockout mice were injected intravenously with 100 mg MDP or buffer, and after 6 hr the amounts of mRNA for 84 proinflammatory genes and 5 house-
keeping genes were measured in feet (or livers, bottom panels) by qPCR and expressed as the ratios of the amount of mRNA in MDP-injected to buffer-injected
mice (which represents fold gene induction by MDP), or as the ratios of fold MDP-induced gene activation in WT to knockout mice (which represents fold
difference in the response to MDP in WT versus knockout mice, WT/knockout). The results are means of 12 WT or 6 knockout mice/group (12 or 6 separate
qPCR assays). The means, SEM, the significance of differences, and the names of the genes are given in Tables S1–3.142 Cell Host & Microbe 5, 137–150, February 19, 2009 ª2009 Elsevier Inc.
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PGLYRP-2, Nod2, and TLR4 in ArthritisFigure 4. MDP and Peptidoglycan Induce Higher Chemokine Levels in Blood in WT Than in PGLYRP-2/ Mice
WT or PGLYRP-2/ mice were injected intravenously with 200 mg PGN or 100 mg MDP, and the concentrations of CCL-2, CCL-12, CXCL-1, and IL-6 were
measured in the serum at the indicated times; means ± SEM of 20–30 mice/group for each time point. The significance of differences between WT and
PGLYRP-2/ mice is indicated.Cell Ho(Figure 5A) and had lower expression of IL-6 mRNA
(Figure 5B). Recombinant mouse PGLYRP-2 protein (but not
recombinant albumin, added to fibroblast cultures at 1 mg/ml)
enhanced expression of IL-6 mRNA induced by bacteria or
IL-1b in PGLYRP-2/ paw fibroblasts to the level seen in WT
fibroblasts (Figure 5B), although by itself PGLYRP-2 did not
induce IL-6mRNA. Stimulation with bacteria induced expression
of PGLYRP-2 mRNA in WT paw fibroblasts (Figure 5C), and
therefore the lack of expression of PGLYRP-2 in PGLYRP-2/
fibroblasts correlated with their low induction of cytokine
mRNA and low secretion of cytokines. These results demon-
strate that PGLYRP-2 enhances cell responsiveness to bacteria
and cytokines and suggest that PGLYRP-2 serves as an endog-
enous mediator of inflammation (has a cytokine-like or alarmin-
like activity).
MDP Induces Expression of PGLYRP-2 in the Feet
through Activation of Nod2
PGLYRP-2 is constitutively expressed in the liver and not in other
tissues (Liu et al., 2001), but its expression is induced by bacteria
or cytokines in fibroblasts (Figure 5C) and in keratinocytes and
other epithelial cells, and not in cells of myeloid origin (mono-
cytes, macrophages, lymphocytes) and endothelial cells (Wang
et al., 2005; Li et al., 2006). By contrast, PGLYRP-3 and
PGLYRP-4 are constitutively expressed in the skin, and their
expression can also be increased by exposure to bacteria or
cytokines (Lu et al., 2006). PGLYRP-2 mRNA was not expressed
in the feet of untreated WT mice, but its expression was induced
following intravenous injection ofMDP (Figures 5D and 5E). Intra-
venous injection of MDP also significantly increased expression
of PGLYRP-3 in the foot (Figure 5D). Stimulation of both
PGLYRP-2 and PGLYRP-3 expression by MDP required Nod2,MDP and Peptidoglycan Induce Higher Chemokine
Levels in Blood in WT Than in PGLYRP-2/ Mice
We next tested whether MDP and peptidoglycan induced higher
chemokine levels in blood in WT than in PGLYRP-2/mice. We
selected three chemokines (CCL-2, CCL-12, and CXCL-1),
which are induced in various tissues and whose mRNA was
induced significantly higher in the feet in WT than in PGLYRP-
2/ mice, and one cytokine (IL-6), which is highly induced in
the liver. Peptidoglycan and MDP (injected intravenously)
induced substantial increases in the levels of all three chemo-
kines in blood in WT mice and significantly lower levels of these
chemokines in PGLYRP-2/ mice (Figure 4). Peptidoglycan
also induced high level of IL-6, which, however, was similar in
WT and PGLYRP-2/. MDP did not induce a significant
increase in IL-6. These results demonstrate lower production
of chemokines in the blood in PGLYRP-2/ than in WT mice
following in vivo challenge with MDP or peptidoglycan, further
supporting the hypothesis that PGLYRP-2 plays a role in induc-
tion of chemokines in vivo.
PGLYRP-2/ Fibroblasts Have Low Responsiveness
to Bacteria and Cytokines, which Is Reconstituted
by Recombinant PGLYRP-2
We next compared the responses of paw fibroblasts from WT
and PGLYRP-2/ mice, because fibroblasts are the main local
source of chemokines (they produce more chemokines than
macrophages) and because we found many proliferating fibro-
blasts in the inflammatory lesions following peptidoglycan or
MDP injection (in addition to infiltrating PMNs). In vitro-cultured
PGLYRP-2/ paw fibroblasts, either unstimulated or stimulated
with peptidoglycan, ReLPS, bacteria, or IL-1b, secreted signifi-
cantly less IL-6, CXCL-1, and CCL-12 than WT paw fibroblastsst & Microbe 5, 137–150, February 19, 2009 ª2009 Elsevier Inc. 143
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PGLYRP-2, Nod2, and TLR4 in Arthritisbecause it was not observed in Nod2/ mice (Figure 5D).
Stimulation of PGLYRP-3 expression by MDP also required
PGLYRP-2, because it was not observed in PGLYRP-2/
mice. Moreover, overexpression of Nod2 (which aggregates
and becomes activated) in HEK293 cells activated PGLYRP-2
promoter (Figure 5F), which demonstrates that Nod2 is sufficient
for induction of PGLYRP-2 expression. These results indicate
that PGLYRP-2 acts downstream of Nod2, because Nod2
induces expression of PGLYRP-2.
PGLYRP-2 Activates Cells and Synergizes with TLR4
and TLR2 In Vitro
We next tested whether PGLYRP-2 directly activates cells or
cooperates with other receptors in cell activation, especially
with TLRs, because Nod2-mediated activation of macrophages
by MDP often synergizes with TLRs (Uehara et al., 2005;
Kobayashi et al., 2005; Kim et al., 2008). Transfection of
HEK293 cells with PGLYRP-2 activated NF-kB transcription
factor and IL-8 promoter, and this activation was not enhanced
by stimulation with bacteria (Figures 5G and 5H). Cotransfection
of HEK293 cells with PGLYRP-2 and TLR2 or TLR4 (plus MD-2
and CD14) enhanced the response of TLR2 or TLR4 to bacteria
(Figures 5G and 5H). These results indicate that PGLYRP-2
directly activates cells and enhances cell activation by TLR2
and TLR4.
TLR4 and MyD88 Are Required in the Effector Phase
of Peptidoglycan- or MDP-Induced Arthritis
Wenext tested whether TLR2, TLR4, orMyD88were required for
peptidoglycan- or MDP-induced arthritis, because PGLYRP-2
synergized with TLR2 and TLR4 in cell activation. Intravenous
injection of peptidoglycan or MDP induced acute arthritis in
TLR2/ mice, manifested by swelling and erythema of ankles
and feet (Figure 6A) with similar kinetics, severity, and incidence
(Figure 6B) as in WT mice. However, neither peptidoglycan nor
MDP induced arthritis in TLR4/ or MyD88/ mice (Figures
6A and 6B).
Although TLR4 was required for the development of peptido-
glycan- or MDP-induced arthritis, activation of TLR4 alone was
not sufficient for the development of arthritis, because WT
mice injected intravenously with a TLR4 agonist, ReLPS, did
not develop arthritis (Figure 6B), despite strong systemicCell Hosresponse to ReLPS injection, manifested by high induction of
cytokines (TNF-a and IL-6) in their blood (Figure S3) and
shock-like appearance (lethargy and rough fur).
To determine whether the requirement for TLR4 in the
development of MDP-induced arthritis was upstream or
downstream of Nod2 and PGLYRP-2, we then tested the level
of MDP-induced chemokine genes in the feet in TLR4/ mice.
Intravenous injection of MDP induced normal activation of proin-
flammatory genes (Figure 6C and Table S3), indicating that TLR4
is required for the development of MDP-induced arthritis down-
stream of Nod2, of PGLYRP-2, and of induction of chemokines
and other proinflammatory genes (which depend on Nod2 and
PGLYRP-2). TLR4 was also not required for MDP-induced
expression of PGLYRP-2 in the feet (Figure 5D). These results
suggest that TLR4 is mainly required in the effector phase of
arthritis, after chemokines and cytokines are generated.
PMNs Are Required for the Development of
Peptidoglycan- or MDP-Induced Arthritis, and TLR4 Is
Required for Expression of CD11b in PMNs and PMN
Recruitment into the Feet
We next tested whether PMNs were required for the develop-
ment of peptidoglycan- and MDP-induced arthritis, because
the most prominent histological feature of this arthritis is infiltra-
tionwith PMNs (Figures 2 and S1). Depletion of PMNs inWTmice
by intravenous injection of anti-PMN Ly-6G (Gr-1) mAb
completely prevented the development of arthritis in peptido-
glycan- or MDP-injected mice (Figure 6D), thus showing that
PMNs are required for the development of peptidoglycan- and
MDP-induced arthritis.
We next tested whether PMNs in our TLR4/ and MyD88/
mice express CD11b, because PMNs in TLR4/ mice have
been shown to lack sufficient expression of integrins, which
makes them defective in adhering to ICAMs and migrating
from blood into the tissues (Zhou et al., 2005). Indeed, PMNs in
our untreated TLR4/ and MyD88/ mice (in contrast to WT
mice) did not express CD11b (Figure 6E). Furthermore, foot
sections from peptidoglycan- or MDP-injected TLR4/ mice
had no PMN infiltrations (Figure S4), which confirms that PMNs
in TLR4/ mice are unable to migrate into the tissues. Thus,
our results indicate that TLR4 plays a permissive role in this
arthritis model (independent of MDP or peptidoglycan), becauseFigure 5. PGLYRP-2/ Fibroblasts Have Low Responsiveness to Bacteria and Cytokines, which Is Reconstituted by PGLYRP-2; MDP
Induces Expression of PGLYRP-2 in the Feet through Activation of Nod2; and PGLYRP-2 Activates IL-8 and NF-kB and Synergizes with
TLR2 and TLR4
(A) IL-6, CXCL-1, and CCL-12 production by paw fibroblasts from WT and PGLYRP-2/ mice cultured with the indicated stimulants.
(B) IL-6mRNA in paw fibroblasts fromWT andPGLYRP-2/mice culturedwith the indicated stimulants and reconstitution of theWT-level response in fibroblasts
from PGLYRP-2/ mice cultured with 1 mg/ml recombinant mouse PGLYRP-2 protein, but not recombinant mouse albumin (rMSA).
(C) PGLYRP-2 mRNA in paw fibroblasts fromWT and PGLYRP-2/mice cultured with the indicated stimulants. For (A)–(C), means ± SEM of three experiments;
significance of differences (WT versus PGLYRP-2/ cells or rMSA versus PGLYRP-2 protein) is indicated by asterisks.
(D) Increase in the amounts of mRNA for PGLYRP-1, PGLYRP-2, PGLYRP-3, and PGLYRP-4 in the feet of WT, PGLYRP-2/, Nod2/, and TLR4/mice 6 hr
after intravenous injection of 100 mg MDP, measured by qPCR and expressed as the ratios of the amount of mRNA in MDP-injected to buffer-injected mice
(means ± SEM of 6–12 mice/group, significance of increase is indicated by asterisks).
(E) Kinetics of induction of PGLYRP-2 mRNA in the feet of WT mice after intravenous injection of 100 mg MDP (means ± SEM of six mice/group).
(F) Induction of PGLYRP-2 transcription in HEK293 cells transfected with PGLYRP-2 promoter-luciferase and control plasmid DNA () or increasing concentra-
tions of Nod2 (means ± SEM of four cultures from two experiments).
(G and H) Induction of IL-8 transcription or NF-kB in HEK293 cells transfected with control DNA, PGLYRP-2, and TLR2 (G) or control DNA, PGLYRP-2, and TLR4
(plus CD14 and MD-2) (H), alone or in combination, after stimulation withMicrococcus, Enterobacter, or ReLPS, or no stimulation. Means ± SEM of seven (G) or
four (H) experiments; significance of differences of PGLYRP-2 versus control DNA or PGLYRP-2+TLR versus TLR is indicated by asterisks. *, p % 0.05; **,
p% 0.005.t & Microbe 5, 137–150, February 19, 2009 ª2009 Elsevier Inc. 145
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PGLYRP-2, Nod2, and TLR4 in ArthritisFigure 6. TLR4, MyD88, and PMNs Are Required for the Development of Peptidoglycan- or MDP-Induced Acute Arthritis
(A) Swelling and erythema of ankles and feet in TLR2/ but not in TLR4/ mice after intravenous injection of 200 mg PGN.
(B) Arthritis scores and incidence in TLR2/, TLR4/, and MyD88/ mice after intravenous injection of 200 mg PGN or 100 mg MDP or in WT mice after intra-
venous injection of 10 mg ReLPS; means ± SEM of 12–20 mice/group.146 Cell Host & Microbe 5, 137–150, February 19, 2009 ª2009 Elsevier Inc.
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PGLYRP-2, Nod2, and TLR4 in ArthritisTLR4 is required in untreated mice for proper maturation of
PMNs and expression of integrins, which are needed for PMN
migration into the tissues in the effector phase of arthritis.
DISCUSSION
Our results demonstrate that mammalian PGRPs, in addition to
their amidase and bactericidal activities, function as modulators
of inflammation and cooperate with other innate immunity
pattern recognition receptors to induce local inflammation. We
show that PGLYRP-2 is required for the development of peptido-
glycan- or MDP-induced local inflammation and arthritis, along
with Nod2 and TLR4, because PGLYRP-2/ mice, Nod2/
mice, and TLR4/ mice are all resistant to peptidoglycan- or
MDP-induced arthritis. The requirement for PGLYRP-2 and
Nod2 correlates with their requirement for MDP-induced
upregulation of chemokine production in the foot. Nod2 works
upstream of PGLYRP-2 and induces expression of PGLYRP-2
in the foot. TLR4 plays a permissive role, as it is required for
the expression of CD11b on PMNs, which is peptidoglycan-
and MDP-independent (it happens before peptidoglycan and
MDP challenge). Thus, the sequence of events in peptidoglycan-
or MDP-induced arthritis is activation of Nod2 by peptidoglycan
fragments, local expression of PGLYRP-2 in the limbs, local
chemokine and cytokine production, and then recruitment of
PMNs into the limbs, which produces acute local inflammation
and arthritis (Figure 7). The chart in Figure 7, however, does
not imply one direct signal transduction pathway in which one
molecule directly activates the next downstream molecule. The
most likely scenario is that after Nod2 induces PGLYRP-2,
Nod2 and PGLYRP-2 are in parallel pathways that are syner-
gistic and complementary and that both pathways are needed
for full induction of gene expression that eventually manifest
themselves in vivo as clinical signs of inflammation. TLR4-
mediated maturation of PMNs is independent of peptidoglycan,
but it affects the outcome of peptidoglycan-induced pathways,
as shown in TLR4/ mice, whose PMNs do not express
CD11b and cannot migrate into tissues.
Our results, therefore, reveal in vivo functions of PGLYRP-2,
Nod2, and TLR4 that define several steps in the pathogenesis
of acute peptidoglycan-induced arthritis (Figure 7) and demon-
strate in vivo interdependence of these three families of pattern
recognition molecules in their requirement for production of local
inflammation. These results are consistent with the emerging
view of in vivo protein function as regulatory networks that are
essential for maintaining immune homeostasis and properly
measured response to infections.
PGLYRP-2 is constitutively produced in the liver and is
secreted into blood (Xu et al., 2004; Zhang et al., 2005; Royet
and Dziarski, 2007). However, PGLYRP-2 from blood does not
significantly contribute to the development of MDP-induced
arthritis, because intravenous injection of PGLYRP-2 into
WT mice, or PGLYRP-2 plus MDP into PGLYRP-2/ mice,
does not induce arthritis (Supplemental Data), and becauseCell Hosbacteria or MDP do not increase the expression of PGLYRP-2
in the liver. Thus, local induction of PGLYRP-2 in the feet is
required for triggering inflammation.
PGLYRP-2 is not constitutively expressed in extrahepatic
tissues, such as skin or the foot, but its expression is induced
by bacteria (Wang et al., 2005; Li et al., 2006) or MDP. Induction
of PGLYRP-2 expression is mediated through Nod2 (as shown
here) and does not involve TLR2 or TLR4 (as shown previously),
is limited to nonimmune cells (epithelial cells, fibroblasts), and is
dependent on the distal regions of the PGLYRP-2 promoter and
different transcription factors than the constitutive expression,
which is dependent on the proximal region of the PGLYRP-2
promoter (Wang et al., 2005; Li et al., 2006). PGLYRP-2 is not ex-
pressed and its expression is not induced in cells of myeloid or
lymphoid origin or in endothelial cells (Wang et al., 2005;
Li et al., 2006). Therefore, monocytes, macrophages, PMNs,
and lymphocytes from PGLYRP-2/ mice are normal
(Supplemental Data). Thus PGLYRP-2/mice show a defective
inflammatory response (no arthritis and low chemokine produc-
tion) only locally in the foot, as reported here, but are not deficient
in the systemic production of macrophage-derived cytokines,
such as TNF-a and IL-6 (Xu et al., 2004).
Although mammalian PGLYRP-2 is an N-acetylmuramoyl-
L-alanine amidase that hydrolyzes bacterial peptidoglycan (Gel-
ius et al., 2003; Wang et al., 2003), its amidase activity is not
required for its proinflammatory effect, because this proinflam-
matory effect is seen with a variety of stimulants that are not
amidase substrates (described in detail in Supplemental Data).
Thus, in addition to its enzymatic activity, which resides in the
Figure 7. Proposed Sequence of Events Leading to PGN- or MDP-
Induced Local Inflammation and Arthritis
The chart indicates temporal sequence of events and does not imply direct
signal transduction pathways. TLR4 permits maturation of PMNs before
exposure to PGN or MDP.(C) Expression of chemokine and cytokine mRNA in the feet of TLR4/ mice after intravenous injection of 100 mg MDP, determined as in Figure 3.
(D) Arthritis scores and incidence in WT mice treated with control IgG or anti-PMN mAb after intravenous injection of 200 mg PGN or 100 mg MDP; means ± SEM
of ten mice/group.
(E) Blood PMNs from untreated TLR4/ and MyD88/ mice, in contrast to WT mice, do not express CD11b integrin detected on western blot.t & Microbe 5, 137–150, February 19, 2009 ª2009 Elsevier Inc. 147
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PGLYRP-2, Nod2, and TLR4 in ArthritisC-terminal PGRP domain (Wang et al., 2003), PGLYRP-2 also
functions as an alarmin, similar to antimicrobial peptides such
as b-defensins, which besides their antimicrobial activity
enhance immune responses and inflammation (Biragyn et al.,
2002).
The role of PGLYRP-2 in arthritis is unique, because other
mammalian PGLYRPs do not have similar proinflammatory
effect. Interestingly, they also do not have the N-terminal do-
main that is unique for PGLYRP-2. Other PGRPs may have an
opposite anti-inflammatory effect, because PGLYRP-1/,
PGLYRP-3/, and PGLYRP-4/ mice all had higher MDP-
induced activation of proinflammatory genes than WT mice.
Moreover, PGLYRP-1/ mice have longer-lasting MDP-
induced arthritis thanWTmice, and PGLYRP-1/PGLYRP-2/
double knockout mice have arthritis of intermediate severity (i.e.,
more severe than PGLYRP-2/ but less severe than WT mice).
PGLYRP-1 is only expressed in the PMNs, and its expression in
other cells is not induced by bacteria or cytokines (Liu et al.,
2000, 2001). The anti-inflammatory function of PGLYRP-1 mani-
fests itself only in the later stages of MDP-induced arthritis,
which is consistent with the local release of PGLYRP-1 from
PMN granules after PMNs’ arrival into the foot. Anti-inflamma-
tory activity of a PMN granule protein (PGLYRP-1) or proteins
present on the skin and in secretions of mouth and intestinal cells
(PGLYRP-3 and PGLYRP-4), which all come in contact with large
numbers of bacteria, would be desirable to limit overresponsive-
ness of the immune system to bacteria.
The absolute requirement for Nod2 in peptidoglycan- or MDP-
induced arthritis and for activation of proinflammatory genes in
the foot demonstrates that Nod2 is the main and required pepti-
doglycan and MDP receptor for these responses in the foot and
that this function cannot be performed by other MDP receptors
(NALP1 andNALP3) or other peptidoglycan receptors. An impor-
tant step in this proinflammatory cascade is induction of
PGLYRP-2 expression, which, as shown here, is induced by
Nod2, but cannot be induced by TLR2 or TLR4 (Wang et al.,
2005).
PGLYRP-2 directly enhances cell responsiveness to bacteria
and cytokines. Fibroblasts from PGLYRP-2/ mice have lower
in vitro responsiveness than fibroblasts from WT mice, and their
responsiveness is reconstituted to the WT level by PGLYRP-2
protein. Moreover, transfection of cells with PGLYRP-2 in vitro
activates these cells, and cotransfection with TLR2 or TLR4
enhances cell activation. This phenomenon is similar to the
synergism between TLRs and Nods (Uehara et al., 2005;
Kobayashi et al., 2005; Kim et al., 2008). In vivo, however,
TLR2 is dispensable, because TLR2/ mice develop strong
peptidoglycan- or MDP-induced arthritis similar to WT mice.
These results suggest that this synergistic interaction between
PGLYRP-2 and TLR2 either is not required for the development
of arthritis or can be performed by other TLRs. Therefore, our
arthritis is different from the intra-articular injection model,
which, unlike our model, is macrophage-, TLR2-, and partially
Nod2-dependent and mimics joint infection (Joosten et al.,
2003, 2008).
TLR4 plays a permissive role for the development of arthritis in
our model, independent of peptidoglycan or MDP stimulation.
The main requirement for TLR4 is for the maturation of PMNs
and expression of CD11b integrin, which happens before148 Cell Host & Microbe 5, 137–150, February 19, 2009 ª2009 Elsepeptidoglycan or MDP challenge, but which is essential for
PMN migration into the tissues in the effector phase of peptido-
glycan- orMDP-induced arthritis. Our results confirm and extend
the results of Zhou et al. (2005), who also showed that TLR4/
mice have greatly reduced expression of CD11b/CD18 integrin,
which is essential for adhesion of PMNs to endothelial cells and
transmigration into the tissues. Moreover, TLR4 is also required
for the responsiveness of PMNs to chemokines (Fan and Malik,
2003), which could additionally contribute to the permissive
role of TLR4 in our arthritis model.
Of note, activation of TLR4 by systemic injection of LPS into
WT mice (in contrast to activation of Nod2 by peptidoglycan)
does not cause arthritis, despite strong systemic and local cyto-
kine production. Such a response to LPS is mostly systemic with
massive production of cytokines in blood and all organs, which
produces a systemic shock-like response (rather than local
response in the foot) and which diverts the effectors, such as
PMNs, to other tissues. By contrast, the in vivo response to
peptidoglycan or MDP is mostly local, which locally triggers
the inflammatory cascade, which then attracts PMNs to the local
sites and results in arthritis.
In summary, our results demonstrate that mammalian PGRPs,
in addition to amidase and bactericidal activities, also have
proinflammatory and anti-inflammatory properties, and that
PGLYRP-2 and Nod2 are both required for the development of
peptidoglycan-induced arthritis. These results reveal new
functions of mammalian PGRPs and Nod2 and demonstrate
interdependence of multiple innate immune pattern recognition
molecules in producing local pathologic changes.
EXPERIMENTAL PROCEDURES
Mice
We generated PGLYRP-1/, PGLYRP-2/, PGLYRP-3/, and PGLYRP-
4/ mice by deleting exons 1, 1–4, 2–5, or 3–4, respectively, and
PGLYRP-1/PGLYRP-2/ double knockout mice by crossing PGLYRP-
1/ with PGLYRP-2/ mice, as described in Supplemental Data. Nod2/,
TLR-2/, TLR-4/, and MyD88/ mice are also described in Supplemental
Data. All mice were backcrossed to BALB/c because this strain is sensitive
to peptidoglycan- and MDP-induced arthritis (Koga et al., 1985; Onta
et al., 1993).
Arthritis Model
To induce experimental acute arthritis (Koga et al., 1985; Onta et al., 1993),
equal numbers of female and male mice (6–12 weeks old) were injected intra-
venously with 200 mg of insoluble peptidoglycan from S. aureus (or from E. coli
or B. subtilis, where indicated, purified as described in Supplemental Data), or
with 100 mg of synthetic MDP (N-acetylmuramyl-L-alanyl-D-isoglutamine) or
MDP-LL (N-acetylmuramyl-L-alanyl-L-isoglutamine) in endotoxin-free saline.
Some mice were injected with Salmonella minnesota Re595 LPS (ReLPS).
The development of arthritis in the hind ankles and feet was evaluated as
described in Supplemental Data using: (1) severity of arthritis, based on
arthritis scores of 0–4; (2) incidence of arthritis; and (3) histological analysis.
The significance of differences in arthritis scores were compared using two-
sample t test and in incidence of arthritis using chi-square test or Yates test
(GB-Stat PPC6.5.6, Dynamic Microsystems).
RNA and Quantitative Real-Time PCR
To measure the expression of proinflammatory genes, RNA was isolated from
both entire hind feet (including ankles) or livers ofmice using the TRIzol method
(Invitrogen), followed by digestion with RNase-free DNase (QIAGEN) and
purification on RNeasy spin columns using RNeasy Minikit (QIAGEN). The
amounts of mRNA for 84 proinflammatory genes and 5 housekeeping genesvier Inc.
Cell Host & Microbe
PGLYRP-2, Nod2, and TLR4 in Arthritiswere measured by qPCR using the Mouse Inflammatory Cytokines and
Receptors RT2 Profiler PCR Array (SA Biosciences) following synthesis of
cDNA from 2 mg of RNA using RT2 PCR Array First Strand Kit (SA Biosciences),
according to themanufacturer instructions (see Supplemental Data). The list of
genes is provided in Table S1. In preliminary experiments, gene activation at
3, 6, and 12 hr post MDP injection was evaluated. The reported results are
from 6 to 12 mice per group, individually assayed 6 hr postinjection (which
was the optimal time for gene activation), or from untreated mice, and the
means ± SEM of the fold increase in each gene expression from 6–12 mice
were calculated. The fold differences (ratios) of >1 or <1 reflect higher or lower
expression levels of the genes (respectively) in WT than in knockout mice.
To determine whether gene activation was statistically significant, one-sample
t test was used (mean fold induction versus 1), and to determine the signifi-
cance of differences in gene activation between two groups of mice (e.g.,
mean fold induction inWT versus knockout mice), two-sample t test was used.
Chemokine and Cytokine Assays
The amounts of chemokines and cytokines were measured by ELISA as
described in Supplemental Data.
Cell Cultures and Transfections
Human HEK293 cells and peritoneal or bone marrow macrophages were
cultured, transfected, stimulated, and assayed as described in Supplemental
Data. Primary mouse paw fibroblasts were isolated, cultured, characterized,
and stimulated as described in Supplemental Data.
PMN Isolation, CD11b Expression, and In Vivo Depletion
Blood PMNswere isolated and assayed for CD11b expression by western blot
as described in Supplemental Data. To deplete PMNs in vivo, mice were
injected intravenously with 200 mg of anti-Ly6G (Gr-1) rat mAb (clone RB6-
8C5 from eBioscience) (Tanaka et al., 2006), which decreased the number of
PMNs in peripheral blood to 6% for at least 3 days. Control mice were
injected with 200 mg rat IgG2bk (eBioscience). Eighteen hours after mAb injec-
tion, mice were injected intravenously with 200 mg peptidoglycan or 100 mg
MDP and scored for arthritis.
SUPPLEMENTAL DATA
Supplemental Data include Supplemental Results, Supplemental Experi-
mental Procedures, Supplemental References, nine figures, and four tables
and can be found online at http://www.cell.com/cellhostandmicrobe/
supplemental/S1931-3128(09)00025-0.
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